Please use this identifier to cite or link to this item: https://doi.org/10.1615/IntJMedMushr.v7.i12.110
Title: Clinical trials for medicinal mushrooms: Experience with Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Lingzhi Mushroom)
Authors: Zhou, S. 
Gao, Y.
Chan, E. 
Keywords: Ganoderma lucidum
Immune function
Lingzhi
Polysaccharide
Reishi
Tumor
Issue Date: 2005
Source: Zhou, S.,Gao, Y.,Chan, E. (2005). Clinical trials for medicinal mushrooms: Experience with Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Lingzhi Mushroom). International Journal of Medicinal Mushrooms 7 (1-2) : 111-117. ScholarBank@NUS Repository. https://doi.org/10.1615/IntJMedMushr.v7.i12.110
Abstract: Despite the popularity of medicinal mushrooms, most are not well researched in terms of clinical efficacy and toxicity. We have completed seven clinical trials of Ganoderma lucidum in several diseases including cancer, Type II diabetes, coronary heart disease, chronic hepatitis B, and neurasthenia. Most of these studies were randomized, double-blind, multi-centered and placebo controlled. The results arising from these studies are promising. For example, treatment with Ganopoly for 12 weeks showed hypoglycemic activity in Type II diabetes, improved the symptoms/signs of patients with coronary heart disease or neurasthenia, and produced some antiviral and liver protective effects in patients with chronic hepatitis B infection. However, the same treatment regimen did not result in any objective response in late-stage cancer patients, although some stable disease status was observed. Ganopoly appeared to enhance immune functions in some cancer patients, but the results have yet to be confirmed. Ganopoly was generally well tolerated. Overall, the findings from all these clinical studies suggest that Ganopoly may have multiple pharmacological activities, although the activities are minor, moderate, or lacking as a result of many factors, such as inappropriate dosage regimen, difficulties in finding suitable biomarkers and end points, large interpatient variability in responses to the treatment, and unknown mode of action. Well designed clinical studies are needed to explore the mode of action, efficacy and safety of G. lucidum in patients. © 2005 by Begell House, Inc.
Source Title: International Journal of Medicinal Mushrooms
URI: http://scholarbank.nus.edu.sg/handle/10635/106629
ISSN: 15219437
DOI: 10.1615/IntJMedMushr.v7.i12.110
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

19
checked on Feb 21, 2018

Page view(s)

28
checked on Feb 24, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.